Regeneron的Q1收入没有达到预期值,但强劲的财政健康以及更多的股权所有权提供了支持。 Regeneron's Q1 earnings miss expectations, but strong financial health and increased stake ownership provide support.

Regenenron制药公司发现Sumitomo Mitsui和KBC集团的股权所有权略有增加,尽管报告的Q1 EPS比预期的低8.22美元,收入下降3.7%,降至30.3亿美元。 Regeneron Pharmaceuticals saw a slight increase in stake ownership by Sumitomo Mitsui and KBC Group, despite reporting a lower-than-expected Q1 EPS of $8.22 and a 3.7% drop in revenue to $3.03 billion. 公司的财政健康依然强劲, 债务与股本比率为0.09, 共识目标价格为822.58, The company's financial health is still strong, with a debt-to-equity ratio of 0.09 and a consensus target price of $822.58, earning a "Moderate Buy" rating from analysts. Regeneron的关键产品,EYLEA, 处理各种眼部状况。 Regeneron's key product, EYLEA, treats various eye conditions.